SURMOUNT-MMO
Research type
Research Study
Full title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults with Obesity
IRAS ID
1006200
Contact name
Ola Khaled
Contact email
Sponsor organisation
Eli Lilly and Company
Clinicaltrials.gov Identifier
Research summary
Obesity affects a large number of people worldwide and is associated with increased obesity-related diseases and death. Obesity is associated with over 200 health complications, including several identified for developing cardiovascular disease and metabolic disease. In 2015, excess body weight accounted for approximately 4 million deaths and 120 million disability-adjusted life years worldwide.
Tirzepatide has the potential of demonstrating clinically meaningful improvements in outcomes
associated with weight loss. Tirzepatide acts like a group of hormones in the body called incretins. Incretin hormones are released when food is eaten and help to reduce blood glucose levels.The purpose of this study, I8F-MC-GPIJ (SURPASS-MMO), is to learn more about the effect of tirzepatide compared to placebo on the reduction of obesity-related diseases and deaths in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population. Study participants will be randomly assigned to receive either tirzepatide or placebo. A placebo looks like the study medication but has no medicine (no therapeutic effect). Neither the study participant themselves nor the study team will know whether the participant is receiving tirzepatide or placebo. Approximately 15,000 participants globally will take part in the study including 150 in the UK. The study will last approximately 5 years.
REC name
East Midlands - Leicester South Research Ethics Committee
REC reference
22/EM/0202
Date of REC Opinion
8 Nov 2022
REC opinion
Further Information Favourable Opinion